| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 |
| filingDate |
1994-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1995-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaa9d21a81bd09a87e9a8fadac70ceb7 |
| publicationDate |
1995-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5464854-A |
| titleOfInvention |
Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
| abstract |
The method of treatment moderating, blocking and/or eliminating premenstrual syndrome embodies the intermittent administering of an AT1 antagonist to a female having menstrual cycles characterized predominately by during substantially the luteal phase inclusive of at least one and frequently by two or more affective and/or autonomic and/or somatic symptoms of substantially incapacitating severity(ies) proximately substantially prior to menses of a menstrual cycle. Losartan is an example of an AT1 inhibitor and is administered either orally or parenterally continuously to a female during her menstrual cycle's luteal phase. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002069191-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005192327-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6294197-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8414920-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6350880-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8226977-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003035832-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009227802-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6858228-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6342247-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6485745-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7413751-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003158244-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018002673-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007254932-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5994348-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005089575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7998953-B2 |
| priorityDate |
1993-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |